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Abstract
Background: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and
inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets that are dysregulated in arthritis
development could provide insight into the aetiology of RA. This study aimed to investigate the composition of the
peripheral blood components, i.e. CD14+ monocytes, CD4+ and CD8+ T lymphocytes (CD3+), CD80+, C-X-C
chemokine receptor 3 (CXCR3)+ and CD27+ B lymphocytes (CD19+), CD16+CD56+CD3− natural killer (NK) cells and
activated CD56+CD3+ T cells, for association with arthritis development in patients with arthralgia.
Methods: Peripheral blood was collected from 89 patients with early RA (disease duration <6 months), 37 healthy
controls (HC) and 113 patients with arthralgia (22 developed arthritis within ≤1 year, 18 developed arthritis after
>1 year and 73 did not develop arthritis). Absolute numbers of monocytes and lymphocyte subsets in whole
heparinized blood were determined with flow cytometry using quantification beads in combination with
fluorescent labelled antibodies for T cells, B cells, monocytes, NK cells and activated T cells.
Results: In patients with early RA, significant decreases in numbers of (activated) T cells, CD80+ and memory B cells
and a trend towards smaller numbers of CD8+ T cells was observed compared to HC. Similar differences were seen
in patients with arthralgia who developed or did not develop arthritis (non-converters), with significantly decreased
CD8+ T cells and memory B cells. Patients with arthralgia who developed arthritis were split into groups that
developed arthritis within 1 year (early converters) or after 1 year (late converters). Late converters had a
significantly decreased number of CD8+ T cells compared to non-converters; early converters had a decreased
number of memory B cells. Longitudinal analysis of converters showed a significant relative increase in CD80+ B
cells towards the conversion time point compared to 24 months prior to conversion.
Conclusions: This study revealed that patients with arthralgia who develop arthritis demonstrate a change in
cellular immune parameters apparent in the periphery, starting with a decrease in cytotoxic T cells 24 months prior
to arthritis development, followed by a decrease in the number of memory B cells 12 months prior to disease
onset.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease af-
fecting the joints. Inflammation of the joints leads to de-
struction of bone and cartilage in the joint [1]. Although
the aetiology of the disease is still unknown it is likely
that inadvertent immune activation is the basis for the
development of RA. Understanding the immune mech-
anism and components that lead to chronic joint inflam-
mation is of utmost importance to allow timely
identification and treatment in order to prevent arthritis
development and concomitant joint destruction.
Among these immune components are autoantibodies
against citrullinated peptides (APCA) and rheumatoid fac-
tor (RF), which are seen years before the clinical manifest-
ation of RA [2, 3]. More recently we have identified the
presence of the type I interferon (IFN) signature in periph-
eral blood cells in 52 % of patients with arthralgia who de-
veloped arthritis within 2 years [4]. Moreover, we provided
evidence that a decreased B cell count, corresponding to
lower memory B cell numbers, in the periphery, is associ-
ated with arthritis development [5].
In this study we analysed the peripheral blood compo-
nents, i.e. CD14+ monocytes, CD4+, CD8+ and CD56+T
lymphocytes (CD3+), CD80+, C-X-C chemokine receptor
3 (CXCR3)+, CD27+ B lymphocytes (CD19+) and CD16+
CD56+CD3− NK cells, for their association with arthritis
development. We therefore, studied individuals who
were seropositive and had joint complaints without
swelling of the joints, i.e. patients defined as having arth-
ralgia. These patients were followed until the develop-
ment of arthritis, defined as having at least one swollen
joint. Furthermore, we investigated the variability of the
frequency of the different cell subsets over the course of
arthritis development in these patients.
Methods
Study population
The Amsterdam Reade cohort used for this study con-
sisted of 113 patients with arthralgia of whom 22 devel-
oped arthritis within 1 year (converters ≤12 months) and
18 developed arthritis after 1 year (converters
>12 months). Inclusion criteria for the patients with
arthralgia were positivity for ACPA and/or RF [6], joint
complaints without clinical arthritis determined by two
independent rheumatologists and a minimum follow-up
period of 24 months. Exclusion criteria for the patients
with arthralgia were the (previous) use of disease-
modifying anti-rheumatic drugs (DMARDs), a history of
arthritis and evidence of erosions on radiographs. Arth-
ritis was defined as having one or more swollen joints as
assessed by two independent rheumatologists. Further-
more, 37 healthy controls (HC) and 89 patients with early
RA were included at Reade. Inclusion criteria for the pa-
tients with early RA were disease duration <6 months and
no previous use of DMARDS or biological agents. See
Table 1 for demographic and clinical characteristics of all
study groups.
Flow cytometry analysis
Absolute numbers and percentage of monocytes and
lymphocyte subsets were determined with flow cytome-
try (FACS Calibur) on whole heparinized blood. Quanti-
fication beads (Trucount, BD) in combination with
CD45 fluorescein isothiocyanate (FITC), CD14 phyco-
erythrin (PE), CD3 peridinin chlorophyll protein (PerCP)
and CD19 allophycocyanin (APC) were used to measure
absolute numbers of lymphocytes, monocytes, B cells
and T cells according to the manufacturer’s instructions.
Absolute numbers of cell subsets were calculated using
the percentage of cells within a main cell type that was
measured with quantification beads. For the subsets
CD45 and CD3 or CD19 were always taken in multiple
tubes combined with the following markers: CD8 PE,
CD4 APC, CD16/56 PE, CXCR3 APC, CD80 PE and
CD27 FITC (all products from BD Biosciences, San Jose,
CA, USA). Flow cytometry data were analysed using
FACSDIVA software version 6.1.3. Forward, sideward
scatter and CD45bright were used to select lymphocytes.
CD16+CD56+CD3− cells were defined as natural killer
(NK) cells and CD16/CD56+ CD3+cells are expected to
be predominantly CD56+CD16−. As CD56+CD3+ T cells,
also described as NK T-like cells, have been described as
activated effector cells [7, 8] we define them here as acti-
vated T cells. Gating strategy is depicted in Additional
file 1: Figure S1.
Statistical analyses
GraphPad Prism 5.0 was used for statistical analysis. The
Mann-Whitney U test or Kruskal-Wallis test followed by
Dunn’s multiple comparison test were used to compare
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the different parameters between patient groups. Log2
values were used for the ratios, showing the timeframe
from conversion time point and 12 or 24 months prior
to conversion. The one sample t test or Wilcoxon signed
rank test was used to test if the median was significantly
different from 0, which would indicate an increase or de-
crease from the conversion time point. P values <0.05
were considered to be significant.
Results
In order to gain insight into the immune differences be-
tween HC and patients with early RA, the number of
circulating monocytes, lymphocytes, NK cells, activated
T cells, B cells, T cells and B and T cell subsets were
assessed by flow cytometry. This revealed that patients
with early RA had a significantly lower overall number
of circulating CD3+ T cells, CD3+CD56+CD16+ activated
T cells, conventional memory (CD27+) B cells and acti-
vated (CD80+) B cells compared to HC (Fig. 1). There
was a similar trend in the number of CD8+ cytotoxic T
cells. The number of monocytes (data not shown), over-
all lymphocytes (data not shown), CD4+ T helper cells, B
cells and migration marker (CXCR3)+ B cells did not dif-
fer between HC and patients with early RA. This indi-
cates that memory B cells may have left the circulation
in patients with early RA.
Next we compared the same lymphocyte subsets at
the inclusion time point in patients with arthralgia who
developed arthritis within 5 years (converters) with
patients with arthralgia who did not develop arthritis
(non-converters). This revealed that converters had a
significant lower number of CD8+ cytotoxic T cells and
CD27+ memory B cells compared to non-converters
(Fig. 2). There was no significant decrease in migration
marker (CXCR3)+ B cells between non-converters and
patients with early arthritis (p = 0.18). A significant de-
crease was observed in CD27+ memory B cells in pa-
tients with early RA compared to non-converters and
HC (p = 0.008 and p = 0.036, respectively). Differences
between HC, non-converters, converters and patients
with early arthritis are depicted in Additional file 2:
Figure S2. This indicates that some of the difference in
the immunological status of patients with early RA have
already occurred in converters by the first visit to the
rheumatologist.
In the Amsterdam Reade cohort, the patients with
arthralgia were followed by a rheumatologist for research
purposes, for a maximum of 5 years, to determine
whether arthritis developed. Therefore, in this cohort,
arthritis could occur between the time point of inclusion
and at a maximum follow up of 5 years. To investigate
whether there was a difference in the composition of cir-
culating mononuclear cells at the inclusion time point
between patients with arthralgia who developed arthritis
within a year and between 1 and 5 years, the converters
were divided into early and late converter groups. This
revealed that the late converters had a significantly lower
number of CD8+ cytotoxic T cells compared to non-
converters (Fig. 3). No differences between late con-
verters and non-converters were observed for B cells,
memory B cells or activation and migration markers. In
the early converters there was a significant decrease in
the number of memory B cells (Fig. 3). The same trend
was visible for the overall number of B cells and the acti-
vation and migration marker-positive B cells.
The data as described suggest that cytotoxic T cells
and memory B cells leave the periphery before the clin-
ical diagnosis of arthritis. To gain more insight into the
Table 1 Demographic characteristics of healthy controls, patients with arthralgia and patients with early RA
Healthy
controls (HC)





<1 year (early converters)
Arthritis development




Individuals (n) 37 113 22 18 73 89
Median age at inclusion in
years (IQR)
30 (27–41) 50 (41–57) 55 (32–65) 45 (39–57) 51 (41–58) 53 (42–60)
Female (n) (%) 16 (64) 86 (76) 17 (77) 14 (78) 55 (75) 59 (66)
ACPA positive (n) (%) N.D. 69 (61) 18 (82) 16 (89) 35 (48) 53 (60)a
RF positive (n) (%) N.D. 50 (44) 12 (55) 5 (28) 33 (45) 49 (55)a
ACPA and RF positive (n) (%) N.D. 29 (26) 11 (50) 6 (33) 12 (16) 43 (48)a
Median follow-up time in
months (IQR)
N.A. 26.9 (19.1–42.4) 8.1 (1.3–12.3) 22.3 (13.9-41.6) 36 (25.7–47.9) N.A.
Median time to arthritis
development in months (IQR)
N.A. 12.48 (7.4–22.1) 8.1 (1.3–12.3) 22.3 (13.9–41.6) N.A. N.A.
aAvailable for 87 out of 89 patients. RA rheumatoid arthritis, HC healthy controls, N.A. not applicable, N.D. not determined, ACPA anti-citrullinated peptide anti-
bodies, RF rheumatoid factor, IQR interquartile range
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Fig. 1 Absolute numbers of cells in the lymphocyte subsets in 89 patients with early rheumatoid arthritis (EAC) and 37 healthy controls (HC). Black
line represents the median of the whole group. Differences between groups were tested using the Mann-Whitney U test. N.S. not significant
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Fig. 2 Absolute numbers of cells per lymphocyte subset in 40 patients with arthralgia who developed arthritis within 5 years (converters) and 73
patients with arthralgia who did not develop arthritis (non-converters). Black line represents median of the whole group. Differences between
groups were tested using the Mann-Whitney U test. N.S. not significant
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Fig. 3 (See legend on next page.)
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time frames of action for these cell types, we investigated
a small group of 17 converters using flow cytometry
measurements at the time point of conversion and 12
and/or 24 months prior to conversion. Additional file 3:
Figure S3 depicts the changes over time in both convert-
ing and 68 non-converting patients with arthralgia. To
more clearly depict the changes in converters at 12 or
24 months prior to conversion, log2 ratios were calcu-
lated to show the relative increase or decrease compared
to the conversion time point. This revealed that there
was a broad distribution within the cell types, where one
patient showed a relative increase towards conversion
and the other revealed a relative decrease towards the
conversion time point (Fig. 4). The most outstanding cell
types were the activation-marker-positive B cells, which
showed a significant relative increase towards the con-
version time point compared to 24 months prior to con-
version. This may indicate that in the very early stages,
possibly years before the development of arthritis, cyto-
toxic T cells and conventional memory B cells migrate
towards the lymph nodes or the joints.
Discussion
Changes in immune parameters and B cells in particular,
have been extensively studied in the peripheral blood of
patients with RA in relation to therapy response, path-
ology of RA and clinical parameters. In patients with
early RA, a decrease in total memory B cells and an in-
crease in serum markers for the activation of B cells
such as beta2 microglobulin have been described [9, 10].
We have recently described lower numbers of memory
B cells as a potential biomarker to predict arthritis de-
velopment in patients with arthralgia [5]. In the present
study, we demonstrate that changes in peripheral blood
mononuclear subsets, especially a smaller number of
CD8+ T cells were seen 24 months prior to developing
arthritis, whereas 12 months prior to arthritis develop-
ment, the number of memory B cells was lower com-
pared to patients with arthralgia who did not develop
arthritis.
Our data demonstrate that there is a clear difference
between patients with early RA and HC, with a decrease
in CD8+ cytotoxic T cells, CD3+CD56+CD16+ activated
T cells, memory B cells and activated B cells in patients
with early RA. This could be partly due to the age differ-
ences between the HC and the patients with early RA,
as it patients with established RA have a prematurely
aged immune system that is about 20 years older than
the healthy controls [11]. However, our data suggest that
these changes start early in the development of RA, as
converters with arthralgia display similar changes. Late
converters had smaller numbers of CD8+ cytotoxic T
cells, whereas the early converters had a decrease in
memory B cells. The smaller number of memory B cells
found in the peripheral blood of early converters and pa-
tients with early RA is similar to what is described by
McComish et al. for DMARD-naïve patients with early
RA [12]. This reduced number could be due to migra-
tion of memory B cells to the synovium of the affected
joints.
We observed trends towards decreased activated B
cells and CXCR3+ B cells, which suggests increased mi-
gration of activated B cells to the joints. These popula-
tions and CD27+ memory B cells may be partly
overlapping [13]. Increased migration of these subsets is
in line with the study of Nanki et al. describing more
memory B cells and CXCR3-positive B cells in the syno-
vium compared to the peripheral blood in patients with
early RA [14]. Alternatively, B cells may have migrated
towards the lymph nodes or bone marrow. In patients
with early RA significantly more B cells were observed
in the draining lymph nodes of the inflamed joints than
in similar lymph nodes among HC [15]. In patients with
established RA the bone marrow adjacent to the affected
joints reveals a cell-rich inflammatory environment in-
stead of a fat-rich non-inflammatory environment as
seen in HC [16]. Both the increase in cells in the lymph
nodes of patients with arthralgia and a more inflamma-
tory environmebn in the bone marrow adjacent to the
affected joints in patients with RA point towards a sys-
temic immune activation in patients with arthralgia in
whome B cells may migrate towards the secondary
lymphoid organs, bone marrow or joints approximately
a year before clinical signs arise.
Reduced numbers of CD8+ cytotoxic T cells are associ-
ated with early arthritis, as there was a trend towards
lower numbers in the patients with early arthritis and a
significant reduction in (late) converters compared to
non-converters. It has previously been described that in
patients with established RA no significant differences
were found in T cell subsets compared to HC;, however
there was a shift seen towards more CD8+ terminally
differentiated effector memory T cells [17]. This might
point towards early activation of cytotoxic T cells in
arthralgia and in patients with early RA, which may later
differentiate into the terminally differentiated effector
memory T cells found in patients with established RA.
There are indications that there is increased migration
(See figure on previous page.)
Fig. 3 Absolute numbers of cells per lymphocyte subset in 73 patients with arthralgia who did not develop arthritis (non-converters), 22 who developed
arthritis within a year (early converters) and 18 who developed arthritis after 1 to 5 years (late converters). Black line represents the median of the whole
group. Differences between groups were tested using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. N.S. not significant
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of CD8+ cytotoxic T cells to the lymph nodes and joints
in patients with RA. In the lymph nodes of patients with
early RA and patients with arthralgia who did not de-
velop RA, there were no differences in the frequency of
total CD8+ cytotoxic T cells. However, there was a
significant increase in activated CD69+ CD8+ T cells in
the lymph nodes of patients with early R, and a tendency
towards this in patients with arthralgia [15]. de Hair et
al., described subtle infiltration of CD8+ cytotoxic T
cells in the synovium of patients with arthralgia [18].
Fig. 4 Negative log2 ratios of the absolute number of cells per lymphocyte subset at the time of arthritis development (conversion) divided by the
absolute number of cells per lymphocyte subset 12 or 24 months prior to arthritis development in 17 patients with arthralgia who developed arthritis.
A ratio >0 indicates increased cell number at 12 or 24 months before arthritis development compared to the conversion time point. Black line
represents the median of the whole group. Differences between the conversion time point and 12 or 24 months prior to arthritis development
(e.g. difference from 0) was tested using the one-sample t test or Wilcoxon signed rank test. *P <0.05, **P <0.01 and ***P <0.001. N.S. not significant
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These data suggest that cytotoxic T cells in patients
with arthralgia become more activated in the lymph
nodes before migrating towards the affected joints,
which might accelerate the inflammation in the joint
by producing more pro-inflammatory cytokines [19].
No differences were observed in CD4+ T helper cells
between HC, non-converters, converters and patients
with early RA. This is in concordance with a recent
publication on CD4+ T cells, reporting no differences
in the absolute number of CD4+ T cells or in CD4+
(terminally differentiated) effector memory cells between
HC and seropositive patients with arthralgia. An increase
in CD4+CD161+ T cells expressing a TH17 or TH1/TH17
phenotype was observed in seropositive patients with
arthralgia compared to HC, suggesting a role for TH17
cells in RA development [20]. Our data suggest that
increased migration of B cell subsets and CD8+ cytotoxic
T cells is reflected by decreased numbers of these subsets
in peripheral blood; however, larger studies are necessary
to confirm this.
Recently seropositive patients with arthralgia were re-
ported to have a decreased percentage of NK cells, espe-
cially CD56dim NK cells, compared to HC [21]; however,
there were no differences in absolute numbers of NK
cells within the CD45+ pool. In our comparison of con-
verting and non-converting seropositive patients with
arthralgia there was no decrease in the absolute numbers
or percentage (data not shown) of overall NK cells; how-
ever, there was no sub-classification of NK cells on
CD56dim or CD56bright. Furthermore, no differences in
NK cells between HC, non-converting and converting
patients with arthralgia and patients with early RA were
observed. This could be due to differences in patient
population and inclusion criteria for the patients with
arthralgia.
Longitudinal data for the patients with arthralgia among
both non-converters and converters show that there was
fluctuation in the percentage of all immune cells that we
measured. This could be a reflection of the normal fluctu-
ation that we also observed in HC or due to seasonal infec-
tions like the influenza virus; however, patients with
symptoms of influenza were asked to return at a later time
point for blood collection. What emerged from the longitu-
dinal data, although from a small cohort, is the significant
increase in the number of activated B cells within patients
between 12 and 24 months before conversion. Our study
provides indications of which immune cell subsets and
changes therein are involved in the phase preceding devel-
opment of clinical RA. Larger studies are needed to better
understand the time points of these changes, as well as the
transitions between the blood, bone marrow, lymph node
and synovial compartments. These studies will enable more
precise prediction for clinical use and the definition of time
points and targets for specific interventions.
Conclusions
The main conclusion from this study is that patients
with arthralgia who develop arthritis have changes in cir-
culating lymphocyte subsets, starting with a decrease in
CD8+ cytotoxic T cells 24 months prior to arthritis de-
velopment, followed by a decrease in the number of acti-
vated memory B cells 12 months prior to disease onset.
Additional files
Additional file 1: Figure S1. Gating strategy of the flow cytometry
analysis. A Gating strategy with quantification beads. Gate 1 for living
cells, which are depicted in the second dot plot. Gate 2 for lymphocytes,
gate 3 for monocytes and gate 4 for the quantification beads. CD3 and
CD19 positivity was determined in the lymphocyte gate and depicted in
plot 5. B Gating strategy for the immunological subsets. Lymphocyte
selection based on FSC and SSC properties (plot 1) followed by selection
on CD45 properties (plot2). All the subsets were determined in the
lymphocyte gate. (TIF 3403 kb)
Additional file 2: Figure S2. Dot plots of the absolute number of cells
in the lymphocyte subsets in 37 healthy controls (HC), 40 patients with
arthralgia who developed arthritis within 5 years (converters), 73 patients
with arthralgia who did not develop arthritis (non-converters) and 89
patients with early RA (EAC). The black line represents median of the
whole group. Differences between groups were tested with the
Kruskal-Wallis test followed by Dunn’s multiple comparison test. N.S. not
significant. (TIF 791 kb)
Additional file 3: Figure S3. Line plot of the absolute number of cells
per lymphocyte subset in 68 non-converting and 17 converting patients
with arthralgia. The non-converting patients are depicted from the time
point of inclusion. The converting patients are depicted from the time
point of conversion and the time before conversion. (TIF 1784 kb)
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